Literature DB >> 19247212

Thyroid remnant ablation in patients with papillary cancer: a comparison of low, moderate, and high activities of radioiodine.

Sanja Kusacic Kuna1, Tatjana Samardzic, Vanja Tesic, Mario Medvedec, Krunoslav Kuna, Irena Bracic, Marija Despot, Damir Dodig.   

Abstract

OBJECTIVE: The consensus about optimal activities of I-131 for thyroid remnant ablation has not yet been achieved. The aim of this study was to compare ablation rates obtained with different I-131 activities. PATIENTS AND METHODS: The study included 466 patients divided into four groups according to I-131 activities given after total thyroidectomy for papillary thyroid cancer: group A [168 patients who received 888 MBq (24 mCi)], group B [125 patients who received 1480 MBq (40 mCi)], group C [65 patients who received 1850 MBq (50 mCi)], and group D [108 patients who received 4440 MBq (120 mCi)]. Ablation outcome was assessed by whole-body scan in hypothyroid state 6-9 months after ablation and finally 18-21 months after the treatment.
RESULTS: The rate of successful ablation was similar in the group of patients who received 24 and 40 mCi (75 and 71.2%, respectively). The higher rate of ablation was achieved in the groups treated with 50 and 120 mCi of radioiodine (87.69 and 90.74%, respectively). The ablation rates at the first follow-up examinations (59.5, 67.2, 73.9, 80.6%) were lower than at second control study (75.0, 71.2, 87.7, 90.7%) in all groups. Time required for thyroid remnant ablation seems to be >or=18 months.
CONCLUSION: Our study indicates that activity of 50 mCi seems to be optimal to achieve a successful ablation rate (approximately 90%). Low I-131 activities are acceptable for lower risk patients because of satisfactory ablation rate (>70%), lower expense, and minimal radiation burden to patients as well as lower radiation exposure to clinical staff. The ablative use of high activities seems neither justified nor optimized.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19247212     DOI: 10.1097/MNM.0b013e3283299992

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  2 in total

1.  The outcome of I-131 ablation therapy for intermediate and high-risk differentiated thyroid cancer using a strict definition of successful ablation.

Authors:  Ken Watanabe; Mayuki Uchiyama; Kunihiko Fukuda
Journal:  Jpn J Radiol       Date:  2017-06-15       Impact factor: 2.374

2.  I-131 for Remnant Ablation in Differentiated Thyroid Cancer After Thyroidectomy: A Meta-Analysis of Randomized Controlled Evidence.

Authors:  Yan Shengguang; Choi Ji-Eun; He Li Lijuan
Journal:  Med Sci Monit       Date:  2016-07-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.